PMC7751497_01
Abstinence was measured by the rate of negative Urine Analysis laboratory tests over the number of total tests during the days in the program period. Figure 2A represents participants in the Brief Medication Assisted Treatment (B-MAT) cohort with >=90 days of enrollment. Figure 2B represents participants in Extended Medication Assisted Treatment (E-MAT) cohort with >=365 days of enrollment. All participants in the E-MAT cohort were also reported in the B-MAT cohort.
nihms-1652932-f0002.jpg
PMC7751497_01_nihms-1652932-f0002.jpg
F2
Figure 2, 75% were abstinent from opioid substances and 59% from all illegal substances found on UA tests for those with 90 days of MAT program enrollment (abstinence was measured as the percentage of UA laboratory test results that were negative over the total tests conducted).
Retention in the Medication Assisted Treatment program was measured by the percentage of patients that remained engaged in pharmacological treatment and psychosocial services over the total patients that started treatment. Figure 3A represents participants in the Brief Medication Assisted Treatment cohort with >=90 days of enrollment. Figure 3B represents participants in the Extended Medication Assisted Treatment (E-MAT) cohort with >=365 days of enrollment. All participants in the E-MAT cohort were also reported in the B-MAT cohort.
nihms-1652932-f0003.jpg
PMC7751497_01_nihms-1652932-f0003.jpg
F3
For those with at least 365 days of MAT enrollment, 84% of participants were abstinent from opioid substances and 62% from all illegal substances. Figure 3 demonstrates a 94% retention rate for participants who have been enrolled for at least 90 days and 58% retention rate for participants enrolled at least 365 days.